131 related articles for article (PubMed ID: 10670416)
21. AMPA receptor antagonist, YM90K, reduces infarct volume in thrombotic distal middle cerebral artery occlusion in spontaneously hypertensive rats.
Yao H; Ibayashi S; Nakane H; Cai H; Uchimura H; Fujishima M
Brain Res; 1997 Apr; 753(1):80-5. PubMed ID: 9125434
[TBL] [Abstract][Full Text] [Related]
22. Neuroprotective effects of a novel AMPA receptor antagonist, YM872.
Small DL; Murray CL; Monette R; Kawasaki-Yatsugi S; Morley P
Neuroreport; 1998 May; 9(7):1287-90. PubMed ID: 9631414
[TBL] [Abstract][Full Text] [Related]
23. Neuroprotective effect of YM90K, an AMPA-receptor antagonist, against delayed neuronal death induced by transient global cerebral ischemia in gerbils and rats.
Kawasaki-Yatsugi S; Yatsugi S; Koshiya K; Shimizu-Sasamata M
Jpn J Pharmacol; 1997 Jul; 74(3):253-60. PubMed ID: 9268085
[TBL] [Abstract][Full Text] [Related]
24. The neuroprotective effect of the novel AMPA receptor antagonist PD152247 (PNQX) in temporary focal ischemia in the rat.
Schielke GP; Kupina NC; Boxer PA; Bigge CF; Welty DF; Iadecola C
Stroke; 1999 Jul; 30(7):1472-7. PubMed ID: 10390325
[TBL] [Abstract][Full Text] [Related]
25. Reduction of cerebral infarct size by non-competitive AMPA antagonists in rats subjected to permanent and transient focal ischemia.
Matucz E; Móricz K; Gigler G; Simó A; Barkóczy J; Lévay G; Hársing LG; Szénási G
Brain Res; 2004 Sep; 1019(1-2):210-6. PubMed ID: 15306255
[TBL] [Abstract][Full Text] [Related]
26. Neuroprotective effects depend on the model of focal ischemia following middle cerebral artery occlusion.
Takamatsu H; Kondo K; Ikeda Y; Umemura K
Eur J Pharmacol; 1998 Dec; 362(2-3):137-42. PubMed ID: 9874163
[TBL] [Abstract][Full Text] [Related]
27. The glutamate AMPA receptor antagonist, YM872, attenuates regional cerebral edema and IgG immunoreactivity following experimental brain injury in rats.
Atsumi T; Hoshino S; Furukawa T; Kobayashi S; Asakura T; Takahashi M; Yamamoto Y; Teramoto A
Acta Neurochir Suppl; 2003; 86():305-7. PubMed ID: 14753458
[TBL] [Abstract][Full Text] [Related]
28. Grey matter and white matter ischemic damage is reduced by the competitive AMPA receptor antagonist, SPD 502.
McCracken E; Fowler JH; Dewar D; Morrison S; McCulloch J
J Cereb Blood Flow Metab; 2002 Sep; 22(9):1090-7. PubMed ID: 12218414
[TBL] [Abstract][Full Text] [Related]
29. Glutamate AMPA receptor antagonist treatment for ischaemic stroke.
Akins PT; Atkinson RP
Curr Med Res Opin; 2002; 18 Suppl 2():s9-13. PubMed ID: 12365832
[TBL] [Abstract][Full Text] [Related]
30. Therapeutic time window of neuroprotection by non-competitive AMPA antagonists in transient and permanent focal cerebral ischemia in rats.
Matucz E; Móricz K; Gigler G; Benedek A; Barkóczy J; Lévay G; Hársing LG; Szénási G
Brain Res; 2006 Dec; 1123(1):60-7. PubMed ID: 17064671
[TBL] [Abstract][Full Text] [Related]
31. Identification of metabolites of [14C]zonampanel, an a-amino-3-hydroxy-5-methylisoxazole-4-propionate receptor antagonist, following intravenous infusion in healthy volunteers.
Minematsu T; Sohda KY; Hashimoto T; Imai H; Usui T; Kamimura H
Xenobiotica; 2005 Apr; 35(4):359-71. PubMed ID: 16019957
[TBL] [Abstract][Full Text] [Related]
32. YM90K: pharmacological characterization as a selective and potent alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate/kainate receptor antagonist.
Shimizu-Sasamata M; Kawasaki-Yatsugi S; Okada M; Sakamoto S; Yatsugi S; Togami J; Hatanaka K; Ohmori J; Koshiya K; Usuda S; Murase K
J Pharmacol Exp Ther; 1996 Jan; 276(1):84-92. PubMed ID: 8558460
[TBL] [Abstract][Full Text] [Related]
33. The AMPA-antagonist talampanel is neuroprotective in rodent models of focal cerebral ischemia.
Erdo F; Berzsenyi P; Andrási F
Brain Res Bull; 2005 Jul; 66(1):43-9. PubMed ID: 15925143
[TBL] [Abstract][Full Text] [Related]
34. Neuroprotection with NBQX in rat focal cerebral ischemia. Effects on ADC probability distribution functions and diffusion-perfusion relationships.
Lo EH; Pierce AR; Mandeville JB; Rosen BR
Stroke; 1997 Feb; 28(2):439-46; discussion 446-7. PubMed ID: 9040703
[TBL] [Abstract][Full Text] [Related]
35. A dose-response study of neuroprotection using the AMPA antagonist NBQX in rat focal cerebral ischemia.
Graham SH; Chen J; Lan JQ; Simon RP
J Pharmacol Exp Ther; 1996 Jan; 276(1):1-4. PubMed ID: 8558416
[TBL] [Abstract][Full Text] [Related]
36. Neuroprotective Mechanisms of Calycosin Against Focal Cerebral Ischemia and Reperfusion Injury in Rats.
Wang Y; Ren Q; Zhang X; Lu H; Chen J
Cell Physiol Biochem; 2018; 45(2):537-546. PubMed ID: 29402799
[TBL] [Abstract][Full Text] [Related]
37. Neuroprotective effects of erythropoietin pretreatment in a rodent model of transient middle cerebral artery occlusion.
Ratilal BO; Arroja MM; Rocha JP; Fernandes AM; Barateiro AP; Brites DM; Pinto RM; Sepodes BM; Mota-Filipe HD
J Neurosurg; 2014 Jul; 121(1):55-62. PubMed ID: 24702327
[TBL] [Abstract][Full Text] [Related]
38. CP-465,022, a selective noncompetitive AMPA receptor antagonist, blocks AMPA receptors but is not neuroprotective in vivo.
Menniti FS; Buchan AM; Chenard BL; Critchett DJ; Ganong AH; Guanowsky V; Seymour PA; Welch WM
Stroke; 2003 Jan; 34(1):171-6. PubMed ID: 12511770
[TBL] [Abstract][Full Text] [Related]
39. Role of organic anion transporters in the pharmacokinetics of zonampanel, an alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate receptor antagonist, in rats.
Minematsu T; Hashimoto T; Aoki T; Usui T; Kamimura H
Drug Metab Dispos; 2008 Aug; 36(8):1496-504. PubMed ID: 18443035
[TBL] [Abstract][Full Text] [Related]
40. [New method for evaluating the effects of neuroprotective therapy in the hemodynamic penumbra].
Sasamata M; Moskowitz MA; Lo EH
Nihon Yakurigaku Zasshi; 2000 Mar; 115(3):161-9. PubMed ID: 10876801
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
